Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Qiagen NV    QGEN   NL0000240000


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

QIAGEN NV : Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2010 Financial Results Call Set for August 10

08/03/2010 | 08:05am US/Eastern

VENLO, The Netherlands, Aug. 3 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN) today announced the Webcast of its second quarter 2010 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, August 10, and will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.

                    Webcast of QIAGEN's second quarter 2010 financial
    What:            results call

    When:           9:30 a.m. EDT on August 10

                    The Webcast is accessible at
    Where:           ConferenceCall

    How:            Log on to the Web at the address above

                    The corresponding presentation slides will be
                    available for download in the investor relations
                    section of QIAGEN's Web site at

                    Andreas Marathovouniotis, Russo Partners, (212)
    Contact:        845-4235

QIAGEN N.V., a Netherlands holding company, is the leading provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include what is considered to be the broadest panel of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer.

QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at

(Minimum Requirements to listen to broadcast: The RealPlayer software, downloadable free from, or The Windows Media Player, downloadable free from and at least a 14.4Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to


Recommend :
React to this article
Latest news on QIAGEN NV
07/29 QIAGEN NV : Reports Second Quarter and First Half 2014 Results and Announces Lau..
07/24 QIAGEN NV : Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatme..
07/15 QIAGEN NV : Advances Leadership in Pre-Analytical Solutions for Next-generation ..
07/01 QIAGEN NV : Acquisitions, Research System Adoption, Magazine Launches, Dividends..
06/18 QIAGEN NV : Receives FDA Approval of artus® CMV RGQ MDx Kit to Monitor Cytomegal..
05/26 QIAGEN NV : receives FDA approval of therascreen® KRAS RGQ PCR Kit paired with s..
05/23 QIAGEN NV : Receives FDA Approval of therascreen® KRAS RGQ PCR Kit Paired with S..
05/20 QIAGEN NV : Integrates Content From BIOBASE, Including Widely Adopted HGMD, With..
05/07 QIAGEN NV : reports first quarter 2014 results and authorizes new $100 million s..
05/06 QIAGEN NV : expands and upgrades Germantown facilities and consolidates Maryland..
Dynamic quotes